



Expert PracticeSM in lung cancer

Chair

Solange Peters, MD, PhD – Switzerland

Faculty

Benjamin Besse, MD, PhD – France

Anne-Marie Dingemans, MD, PhD – the Netherlands

Wolfgang Jungraithmayr, MD, PhD – Switzerland

Keith Kerr, MD, FRCPath – United Kingdom

Natasha Leighl, MD, MMSc, FRCPC – Canada

Umberto Ricardi, MD, PhD – Italy

Register online at

www.prIMEoncology.org/EPLung_Prague2014

For available travel grants, please email
travelgrants@prIMEoncology.org

Agenda

Saturday, 13 December

- 08.30 Welcome, introduction, and demographics
prIME Medical Director and Solange Peters, MD, PhD
- 08.50 The role of pathology in the era of targeted therapy
Keith Kerr, MD, FRCPath
- 09.20 Keynote lecture—Immunotherapy: A step forward in treatment of advanced NSCLC
Solange Peters, MD, PhD
- 09.50 Case #1—Stage III NSCLC: What's the best multimodality approach?
Wolfgang Jungraithmayr, MD, PhD; Umberto Ricardi, MD, PhD; Benjamin Besse, MD, PhD
- 10.50 Coffee break

Welcome

On behalf of Solange Peters, MD, PhD, meeting chair, we are pleased to invite you to the *Expert PracticeSM in Lung Cancer* meeting in Prague, Czech Republic, on 13 December 2014.

During this case-based meeting, leaders in the field will discuss, in an interactive format, clinical issues encountered daily by practicing physicians.

Target Audience

This educational activity is intended for Pan-European medical oncologists, radiation oncologists, thoracic surgeons, pulmonologists, pathologists, and other oncology professionals interested and/or involved in the management of patients with non-small cell lung cancer (NSCLC).

Meeting Venue

andel's Hotel Prague

Stroupežnického 21
150-00 Prague 5
Czech Republic

- 11.10 Case #2—Advanced NSCLC: Treatment strategies in the absence of targetable driver mutations
Benjamin Besse, MD, PhD
- 11.55 Case #3—Adenocarcinoma with *ALK* rearrangement: Selecting optimal approach
Natasha Leighl, MD, MMSc, FRCPC
- 12.40 Lunch
- 13.40 Clinical opinion poll questions: Challenging the experts
- 14.10 Case #4—*EGFR*-mutated advanced NSCLC: Evaluating treatment options
Anne-Marie Dingemans, MD, PhD
- 14.55 Case #5—Squamous cell lung carcinoma: The changing treatment paradigm
Natasha Leighl, MD, MMSc, FRCPC
- 15.40 Concluding remarks
Solange Peters, MD, PhD